Advances continue to be made in the diagnosis and treatment of multiple myeloma, leading to improved patient care and outcomes….
Novel concepts and combinations for high-risk AML: updates from ASH 2018
Expert interviews and presentations from the ASH 2018 meeting. Spelling promise for high-risk MDS patients.
The definitive guide to multiple myeloma at ASH 2018
Leading AML experts discuss novel therapeutic approaches and clinical trial data for high-risk AML. Discover more by exploring exclusive interviews…
Explore the latest updates from Myeloma2018 with new e-learning webcasts available now!
VJHemOnc is pleased to bring you e-learning webcasts from iwAL 2018. Catch up on key topics in acute leukemia now!
Explore our promotional feature on the biosimilar rituximab, Truxima®. Prescribing information is available on the following page.